An Official Website of the United States Government
Company Information:
Name:
THERAPYX, INC.
Address:
138 FARBER HALL
3435 MAIN STREET
BUFFALO, NY 14214-
3435 MAIN STREET
BUFFALO, NY 14214-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
TUMOR VACCINE:COVALENT LINK OF ANTIGEN TO DENDRITIC CELL
Award Year / Program / Phase:
2002 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Qiang Lou
Award Amount:
$158,517.00
Abstract:
DESCRIPTION (provided by applicant): The ability of dendritic cells (DC) to activate naive T-cells has made them targets for the design of enhanced vaccination protocols. DC loaded with tumor antigens in vitro and injected into recipients, have induced protective immune responses in several… More
TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Nejat K. Egilmez
Award Amount:
$0.00
Abstract:
DESCRIPTION (provided by applicant):
Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demonstrated in Phase I studies. A single intra-tumoral injection of Interleukin-12-encapsulated… More
TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES
Award Year / Program / Phase:
2003 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Nejat K. Egilmez
Award Amount:
$2,555,134.00
Abstract:
DESCRIPTION (provided by applicant):
Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demonstrated in Phase I studies. A single intra-tumoral injection of Interleukin-12-encapsulated… More
Treatment of Type 2 Diabetes with Oral Administration of Nanoencapsulated GLP-1
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Thomas F. Conway
Award Amount:
$144,961.00
Abstract:
DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the leading causes of death and disability in the world. While current treatments prevent some of diabetes' more damaging complications, they can neither restore normoglycemia nor eliminate all the harmful effects caused by long… More
Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$292,501.00
Abstract:
DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral strains like avian influenza and the emergence of antibiotic
resistant forms of long established… More
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$172,500.00
Abstract:
DESCRIPTION (provided by applicant): The disorders collectively known as inflammatory bowel disease (IBD) include Crohn's disease (CD) and ulcerative colitis (UC) and affect up to one million people in the US. Both UC and CD result from uncontrolled chroni
c inflammatory activity in the GI tract.… More
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Thomas F. Conway – 716-829-2528
Award Amount:
$2,999,994.00
Abstract:
DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and… More